White Paper

Changing Minds? Unlocking the Potential of Psychedelics in Mental Health Therapy

Explore the growing interest in research around psychedelic substances for medical applications related to workers' comp populations, including but not limited to psilocybin, ketamine, and MDMA.

White Paper Summary

Traditionally perceived to be recreational party drugs, the science behind psychedelics’ medical benefits has come quite far in the last decade. According to recent clinical developments, the altered sense of thinking and feeling caused by psychedelics can lead to mental health breakthroughs when appropriately navigated by qualified clinicians.

Certain researchers believe psychedelics have the potential to change the mental health landscape, making it important to understand their relevance to workers’ comp.

By the end of this year a major psychedelic could receive FDA approval for the treatment for PTSD. These developments increase the potential for more drug approvals to come in the next few years. And while there are federal complications as most psychedelics are classified as Schedule I drugs, there is a growing wave of psychedelic decriminalization at a more local level.

For more content like this from Healthesystems visit their RxInformer clinical journal website.

Healthesystems is a leading provider of Pharmacy Benefit Management (PBM) & Ancillary Benefits Management programs for the workers' compensation industry.

More from Risk & Insurance